Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.85 0.00 08:00:20
Bid Price Offer Price High Price Low Price Open Price
1.80 1.90 1.85 1.85 1.85
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.84 -0.85 3
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 1.85 GBX

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Investors    N4 Pharma Takeover Rumours

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
15/1/202311:33N4 Pharma3,897
20/5/202107:25N4 Pharma - Making good drugs better.4,391
14/9/202006:40N4P Covid-19 Wealth Warning108

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-02-06 12:27:311.8325,000456.25O
2023-02-06 09:57:131.8328,000511.00O
2023-02-06 09:47:331.915249.99O
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

Top Posts
Posted at 18/11/2022 09:53 by goforgold1
Fuvking hell Turner Pope . The cowboys of AIM . This share is doomed it's either TP or Death Spiral Loan . Wow Another con full of them at moment . Never buy a share from were TP involved your lose everything
Posted at 18/11/2022 09:48 by nobbygnome
Wow, bid below the placing price!
Posted at 18/11/2022 07:15 by nobbygnome
Ouch. Further massive dilution at a very low price!
Posted at 01/11/2022 12:45 by ch1rp
I think N4P know a little bit more than you Nobbs. After all you have been shorting here for years.
Posted at 04/10/2022 06:16 by jakleeds
Looks very promising

4 October 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Double siRNA Testing Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R) , a novel delivery system for cancer treatments and vaccines, is pleased to announce successful in vitro testing of Nuvec(R) loaded with two small interfering RNA (siRNA) probes.

On 14 September 2022, the Company announced a strategic update highlighting its intention to focus its further development work on multiple loaded siRNA on Nuvec(R) .

T he Company has now completed initial in vitro testing of Nuvec(R) loaded with two generic siRNA probes, GFP (Green Fluorescent protein) and EHMT-2 (Euchromatic Histone Lysine Methyltransferase 2 ) at the same time. The siRNA probes were loaded onto Nuvec(R) in equal amounts, at a concentration previously shown to be active. Testing demonstrated that both siRNA probes when loaded onto Nuvec(R) were able to significantly silence their respective targets.

Nigel Theobald, Chief Executive Officer of the Company, commented :

"Showing that Nuvec(R) loaded with two generic siRNA probes still achieves significant silencing of their respective genes is validation for us to now begin the further work that we announced on 14 September with EGFR and BCl-2 in a PC9 lung cancer model.

"Achieving the initial successful testing of Nuvec (R) with the generic GFP and EHMT-2 siRNA will also allow us to commence commercial outreach discussions which will only be further strengthened by the results from the new work we are undertaking ."

Posted at 14/6/2022 12:10 by ch1rp
? If you think that then get out the share.
Posted at 14/2/2022 10:48 by pwal
N4P has got all these patents but when are we going to see sales??
Posted at 14/12/2021 13:41 by andymunchkin
Master RSI28 Aug '20 - 11:57 - 2797 of 3785
0 1 0
Able to buy at middle price 11.675p ( 11.50 v 11.75p )

Only WINS at offer
2 at bid
Master RSI28 Aug '20 - 12:05 - 2798 of 3785
0 3 0
that's it no more cheap shares, WINS has gone to 12p again

12p 30,000 WINS 13:00
Hi MusterBater whats WINS @ now cheers. Btw uSoundLike RampngBufoon whysTht????

Posted at 13/12/2021 11:15 by earwacks
The rns is obviously unexpected as Nigel admitted the results were 'unexpected.' The point is the trials continue on the vaccine at no cost to N4P. Unfortunately that means no revenue continuing for the time being. However I don't see this as a change in strategy, rather a continuation. The results from Gene therapy have been very encouraging showing not just a suppression in tumours but also a reduction. So why would they not progress this further. Market reaction is understandable. In the longer term I see more positives than negatives. Fortunately this is not a one trick pony
Posted at 27/7/2021 22:08 by tankerton
The share price Angel analyst report suggested that N4`s share price should be 10 times higher than its current price to align it to its peers.
Even at 10 times its current valuation, there would still be a strong argument for a takeover but at its current valuation, it would be a sitting duck to an opportunistic bid.
Thankfully I don`t expect N4 to remain at this valuation for much longer as we have a number of big news items coming up.

N4 Pharma share price data is direct from the London Stock Exchange
Your Recent History
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230207 08:46:44